时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
These pathological abnormalities are associated with neuronal cell death, accelerated structural brain atrophy, and reduced glucose metabolism in patients affected by AD dementia,, Furthermore, AD remains the predominant cause of dementia in individuals over 65 years old and is the seventh leading cause of death in the United States.
方法
It is approved by the US Food and Drug Administration for the treatment of motor disorders such as Parkinson's disease (PD), tremor, and dystonia.；Collectively, nine studies met the inclusion criteria, and their designs, stimulation parameters, targets, and key findings are summarized in .–,,,– DBS directly targets neural circuits affected in AD and offers a potential means of improving cognition, behavior, and quality of life where current treatments fall short.；Six patients meeting National Institute of Neurological and Communicative Disorders and Stroke (NINCDS)-Alzheimer′s Disease and Related Disorders Association (ADRDA) criteria for probable AD, Mini-Mental State Examination (MMSE) scores between 18 and 28, a Clinical Dementia Rating (CDR) score of 0.5 or 1.0, and stable cholinesterase inhibitor use for at least 6 months were enrolled and underwent bilateral electrode implantation.
核心结论
These pathological abnormalities are associated with neuronal cell death, accelerated structural brain atrophy, and reduced glucose metabolism in patients affected by AD dementia,, Furthermore, AD remains the predominant cause of dementia in individuals over 65 years old and is the seventh leading cause of death in the United States.；Although there is currently no effective prophylaxis or cure for AD, several pharmacological and nonpharmacological interventions have been proven to delay disease progression.；These noninvasive techniques modulate activity in cortical regions involved in memory and executive function, most commonly the dorsolateral prefrontal cortex, right inferior frontal gyrus, or temporoparietal regions. ‖ 结论：These findings are consistent with broader neuromodulation research showing that circuit-level interventions may stabilize functional networks even in progressive neurodegenerative disorders.
局限
Murrow's model proposes that DBS-f can activate both synchronized and unsynchronized pathways, which may explain downstream cerebellar and sensorimotor engagement observed in the ADvance trial., However, DBS may not be purely excitatory.；This situation suggests that hippocampal integrity may not be sufficient to sustain cognitive function on its own as AD progresses.；Given that younger-onset AD represents only 4% of AD cases and is marked by more severe network disruption, these results reflect disease severity rather than age and should not be generalized to the broader AD population.,, Across stimulation targets, outcomes were influenced by patient characteristics, particularly disease sta
对本项目的价值
★☆☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
全文来源
PMC JATS 全文（正文 66,642 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Deep brain stimulation in Alzheimer's disease.
- 期刊与标识：J Alzheimers Dis Rep · PMID 42947905 · DOI 10.1177/25424823261441166
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。